A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

Capnia, Inc.6 sites in 1 country30 target enrollmentSeptember 2015

ConditionsTrigeminal Neuralgia

InterventionsCarbon Dioxide Drug Delivery System (CDDS)

DrugsCarbon Dioxide Drug Delivery System (CDDS)

Overview

Phase: Phase 2
Intervention: Carbon Dioxide Drug Delivery System (CDDS)
Conditions: Trigeminal Neuralgia
Sponsor: Capnia, Inc.
Enrollment: 30
Locations: 6
Primary Endpoint: Pain relief assessed on a visual analog scale (VAS) in a subject diary
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.

Registry

clinicaltrials.gov

Start Date

September 2015

End Date

April 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Capnia, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male and female, 18 years of age and older.
•History of classical trigeminal neuralgia with or without persistent background facial pain, not secondary, as defined by International Classification of Headache Disorders (ICHD), third edition, beta version (ICHD-3 beta, Cephalalgia 2013).
•Diagnosis of trigeminal neuralgia (TN) for at least 60 days prior to enrollment.
•Experience pain with a score of at least 5 on a 0-10 scale during a typical TN episode as reported by subject. Note: Prior to treatment pain score must a 5 or greater on a VAS.
•History of unilateral typical TN pain predominantly in the V2 branch of the trigeminal nerve.
•Absence of a significant structural lesion (e.g., a tumor) as the cause of pain as shown in at least one neuro-imaging study.
•On stable dose of all medications, including those for the treatment of TN prevention/prophylaxis, for at least 14 days prior to baseline (including, but not limited to, verapamil, lithium, melatonin, any anticonvulsant, any systemic corticosteroid or steroid injection, occipital nerve block, other cranial or extracranial nerve block, or any neurostimulation treatment). Note: Subjects are allowed to use their usual standard of care for the acute/abortive treatment of trigeminal neuralgia attacks 60 or more minutes after the initial dose, provided it is approved by the investigator.
•Capable of completing a diary.
•Able to provide written Informed Consent.

Exclusion Criteria

•Are unable to comply with protocol requirements.
•Have recent of alcohol or drug abuse within 2 years prior to study enrollment.
•Current major psychiatric disorder: suicidal ideation, bipolar, panic disorder, schizophrenic, or psychosis. Subjects who are documented as clinically stable and not exhibiting symptoms related to their psychiatric disorder are eligible.
•History of asthma (other than mild or intermittent).
•Have an existing serious unstable systemic disease (e.g., severe emphysema, other respiratory diseases, heart disease, etc.) that precludes participation.
•Clinically significant nasal disorder (deviated septum, presence of polyps, evidence of significant congestion, rhinitis, or other nasal abnormalities) that prevents unrestricted breathing through each nostril.
•Currently on anticoagulants or have a diagnosis of a bleeding disorder.
•Current diagnosis of fibromyalgia, temporomandibular disorders (TMD), odontogenic pain or other orofacial pain.
•Surgery for treatment of TN within 30 days prior to screening. Note: Investigator must ensure that patients who have had surgery have recovered and are not experiencing any side effects from surgery for treatment of TN
•Females who are pregnant or breast-feeding and/or plan to become pregnant or to breast-feed during study participation or within 30 days after treatment.

Arms & Interventions

Treatment

All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.

Intervention: Carbon Dioxide Drug Delivery System (CDDS)

Outcomes

Primary Outcomes

Pain relief assessed on a visual analog scale (VAS) in a subject diary

Time Frame: Assessed through 24 hours from initial dose

Secondary Outcomes

Percentage of subjects experiencing pain freedom at 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary(Assessed through 60 minutes post intial dose)
Reduction in the number of attacks (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Increase in duration between episodes of pain (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Percentage of subjects with pain relief 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary(Assessed through 60 minutes post intial dose)
Rescue medication usage (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Subject satisfaction (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Attack recurrence (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Decreased trigger sensitivity (recorded in a subject diary)(Assessed through 24 hours from initial dose)
Reported Adverse Events (recorded in a subject diary and during follow up phone calls)(Up to 7 days after inital dose)
Reduction in intensity of attacks (recorded in a subject diary)(Assessed through 24 hours from initial dose)